NCT06423352

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

A Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.

Conditions

• Mild to Moderate Hypertension

Interventions

Type	Name	Description
DRUG	Zilebesiran	Zilebesiran administered by subcutaneous (SC) injection
DRUG	Placebo	Placebo administered by SC injection

Timeline

• Start date: 2024-06-05
• Primary completion: 2025-07-17
• Completion: 2025-07-17
• First posted: 2024-05-21
• Last updated: 2025-08-29

Locations

3 sites across 1 country: Japan

Regulatory

• FDA-regulated drug study